Net revenue grew 34% in Q3 and 13% for the nine-month period, with EBITDA losses narrowing year-over-year. The company secured a SEK 30 million loan facility, expanded its product portfolio, and faces higher logistics costs due to geopolitical factors.Original document: Newbury Pharmaceuticals AB…
Net revenue grew 34% in Q3 and 13% for the nine-month period, with EBITDA losses narrowing year-over-year. The company secured a SEK 30 million loan facility, expanded its product portfolio, and faces higher logistics costs due to geopolitical factors.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.